Bacil Pharma (524516) Q1 26/27 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended 30th June 2026, with results reviewed by the Audit Committee and subject to a limited review by statutory auditors.

• Financial statements prepared in compliance with Indian Accounting Standards (Ind AS) and SEBI regulations.

Financial highlights

• Revenue from operations for the quarter was ₹8.91 lakhs, unchanged year-over-year and down from ₹11.34 lakhs in the previous quarter.

• Total expenses for the quarter were ₹2.27 lakhs, significantly lower than ₹7.45 lakhs in the previous quarter and ₹10.90 lakhs in the same quarter last year.

• Profit before tax was ₹6.64 lakhs, up from ₹3.89 lakhs in the previous quarter and a loss of ₹89.40 lakhs in the same quarter last year.

• Profit after tax was ₹30.12 lakhs, compared to a loss of ₹164.14 lakhs in the previous quarter and a profit of ₹66.90 lakhs in the same quarter last year.

• Other comprehensive income for the quarter was ₹31.73 lakhs, compared to a loss of ₹226.30 lakhs in the previous quarter.

Key financial ratios and metrics

• Basic and diluted EPS for the quarter were ₹0.22, compared to ₹0.44 in the previous quarter and ₹0.48 in the same quarter last year.

• Paid-up equity share capital stood at ₹1,397.03 lakhs.